About: Amesergide

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Amesergide (INN, USAN; developmental code name LY-237733) is a serotonin receptor antagonist of the ergoline and lysergamide families related to methysergide which was under development by Eli Lilly and Company for the treatment of a variety of conditions including depression, anxiety, schizophrenia, male sexual dysfunction, migraine, and thrombosis but was never marketed. It reached phase II clinical trials for the treatment of depression, erectile dysfunction, and premature ejaculation prior to the discontinuation of its development.

Property	Value
dbo:abstract	Amesergide (INN, USAN; developmental code name LY-237733) is a serotonin receptor antagonist of the ergoline and lysergamide families related to methysergide which was under development by Eli Lilly and Company for the treatment of a variety of conditions including depression, anxiety, schizophrenia, male sexual dysfunction, migraine, and thrombosis but was never marketed. It reached phase II clinical trials for the treatment of depression, erectile dysfunction, and premature ejaculation prior to the discontinuation of its development. (en)
dbo:casNumber	121588-75-8
dbo:chEMBL	160293
dbo:fdaUniiCode	EJL329H95R
dbo:kegg	D02893
dbo:pubchem	9821951
dbo:thumbnail	wiki-commons:Special:FilePath/Amesergide.svg?width=300
dbo:wikiPageExternalLink	http://adisinsight.springer.com/drugs/800001117 https://pdsp.unc.edu/databases/pdsp.php%3FknowID=0&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testDDRadio=testDDRadio&testLigandDD=782&testLigand=&referenceDD=&reference=&KiGreater=&KiLess=&doQuery=Submit+Query
dbo:wikiPageID	55333298 (xsd:integer)
dbo:wikiPageLength	10913 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1113805420 (xsd:integer)
dbo:wikiPageWikiLink	dbc:5-HT2B_antagonists dbc:5-HT7_antagonists dbr:Potency_(pharmacology) dbr:Schizophrenia dbr:Depression_(mood) dbr:Dopamine_receptor dbc:Abandoned_drugs dbc:Isopropyl_compounds dbr:Noradrenergic_and_specific_serotonergic_antidepressant dbr:Oral_administration dbr:Eli_Lilly_and_Company dbr:Mirtazapine dbr:Erectile_dysfunction dbr:Anxiety dbr:Clinical_trial dbr:Receptor_antagonist dbr:Pharmacodynamics dbr:Premature_ejaculation dbr:Muscarinic_acetylcholine_receptor dbc:5-HT2C_antagonists dbr:Active_metabolite dbc:Alpha-2_blockers dbr:5-HT1A_receptor dbr:5-HT1B_receptor dbr:5-HT1D_receptor dbr:5-HT1E_receptor dbr:5-HT1F_receptor dbr:5-HT2A_receptor dbr:5-HT2B_receptor dbr:5-HT2C_receptor dbr:5-HT2_receptor dbr:5-HT3_receptor dbr:5-HT4_receptor dbr:5-HT5A_receptor dbr:5-HT6_receptor dbr:5-HT7_receptor dbc:5-HT2A_antagonists dbc:Antidepressants dbc:Anxiolytics dbr:Alpha-1_adrenergic_receptor dbr:Alpha-2_adrenergic_receptor dbr:Ergoline dbr:Histamine_H1_receptor dbr:Histamine_receptor dbc:Lysergamides dbr:Affinity_(pharmacology) dbr:Binding_selectivity dbr:Dopamine_D1_receptor dbr:Dopamine_D2_receptor dbr:D1_receptor dbr:D2_receptor dbr:D3_receptor dbr:D4_receptor dbr:D5_receptor dbr:H1_receptor dbr:Methysergide dbr:Migraine dbr:Phases_of_clinical_research dbr:Serotonin_receptor_antagonist dbr:Thrombosis dbr:Serotonin_receptor dbr:Alpha-1_adrenergic dbr:Male_sexual_dysfunction dbr:Beta_adrenergic_receptor dbr:Lysergamide
dbp:c	25 (xsd:integer)
dbp:casNumber	121588 (xsd:integer)
dbp:chembl	160293 (xsd:integer)
dbp:chemspiderid	7997700 (xsd:integer)
dbp:h	35 (xsd:integer)
dbp:iupacName	-N-Cyclohexyl-7-methyl-4-propan-2-yl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (en)
dbp:kegg	D02893 (en)
dbp:n	3 (xsd:integer)
dbp:o	1 (xsd:integer)
dbp:pubchem	9821951 (xsd:integer)
dbp:routesOfAdministration	dbr:Oral_administration
dbp:smiles	CCN1C=C2C[C@@H]3[C@H]C5=C2C1=CC=C5 (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	KEMOOQHMCGCZKH-JMUQELJHSA-N (en)
dbp:synonyms	LY-237733; N-Cyclohexyl-11-isopropyllysergamide (en)
dbp:title	dbr:Pharmacodynamics
dbp:titlestyle	background:#ccccff (en)
dbp:unii	EJL329H95R (en)
dbp:width	125 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Abbr dbt:Adrenergic_receptor_modulators dbt:Commonscatinline dbt:Drugbox dbt:Navboxes dbt:Reflist dbt:Serotonin_receptor_modulators dbt:Short_description dbt:Abbrlink dbt:Dopamine_receptor_modulators dbt:Ergolines
dcterms:subject	dbc:5-HT2B_antagonists dbc:5-HT7_antagonists dbc:Abandoned_drugs dbc:Isopropyl_compounds dbc:5-HT2C_antagonists dbc:Alpha-2_blockers dbc:5-HT2A_antagonists dbc:Antidepressants dbc:Anxiolytics dbc:Lysergamides
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment	Amesergide (INN, USAN; developmental code name LY-237733) is a serotonin receptor antagonist of the ergoline and lysergamide families related to methysergide which was under development by Eli Lilly and Company for the treatment of a variety of conditions including depression, anxiety, schizophrenia, male sexual dysfunction, migraine, and thrombosis but was never marketed. It reached phase II clinical trials for the treatment of depression, erectile dysfunction, and premature ejaculation prior to the discontinuation of its development. (en)
rdfs:label	Amesergide (en)
owl:sameAs	wikidata:Amesergide dbpedia-fa:Amesergide https://global.dbpedia.org/id/2Y1V3
prov:wasDerivedFrom	wikipedia-en:Amesergide?oldid=1113805420&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Amesergide.svg
foaf:isPrimaryTopicOf	wikipedia-en:Amesergide
is dbo:wikiPageRedirects of	dbr:LY-237,733 dbr:LY-237733 dbr:LY237,733 dbr:LY237733 dbr:LY_237,733 dbr:LY_237733
is dbo:wikiPageWikiLink of	dbr:C25H35N3O dbr:Lysergamides dbr:List_of_drugs:_Am dbr:LY-237,733 dbr:LY-237733 dbr:LY237,733 dbr:LY237733 dbr:LY_237,733 dbr:LY_237733
is foaf:primaryTopic of	wikipedia-en:Amesergide